Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
The PCMPA has slammed Moderna over an unapproved WhatsApp message that offered children 1,500 pounds sterling ($2,000) to ...
Moderna (NASDAQ:MRNA) shares snapped six straight sessions of losses, as the stock closed 0.46% higher at $63.93 on Thursday.
Shares of Moderna Inc. MRNA inched 0.46% higher to $63.93 Thursday, on what proved to be an all-around positive trading ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback